Rituximab-induced Pulmonary Function Changes

NCT01632124 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2012-06-29

No results posted yet for this study

Summary

Measuring lung function (FVC, FEV1, DLCO) before, during and after treatment with rituximab in patients with rheumatoid arthritis or inflammatory myositis.

Conditions

Interventions

OTHER

Lung function measurement

Spirometry and measurement of diffusing capacity for carbon monoxide

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Daniel Franzen, MD · University Hospital Zurich, Division of Internal Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632124 on ClinicalTrials.gov